Safety and Effectiveness Study of the Reflection Ceramic Acetabular System (RCH)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This Post-Approval study is prospective follow-up study designed to evaluate the long-term safety and effectiveness of the Reflection Ceramic Acetabular System.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis |
Device: Reflection Ceramic-Ceramic Total Hip Replacement Device: Reflection FSO V Total Hip Replacement |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Post Approval Study: Reflection Ceramic Acetabular System |
- Number of revisions, radiographic assessment, Harris Hip Score (Hip function and radiographic review) [ Time Frame: [Time frame: 3, 6, 12, 24,36,48,60 months] ] [ Designated as safety issue: Yes ]
- All adverse events reported through 5 year post-operative. [ Time Frame: Intraoperative through 5 year post-operative ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 345 |
| Study Start Date: | December 2004 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
|
Device: Reflection Ceramic-Ceramic Total Hip Replacement
Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
Other Names:
|
|
Active Comparator: 2
Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
|
Device: Reflection FSO V Total Hip Replacement
Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
Other Names:
|
Detailed Description:
This Post-Approval study is prospective follow-up study designed to evaluate the long-term safety and effectiveness of the Reflection Ceramic Acetabular System. Randomized Non-inflammatory Arthritis, Randomized Inflammatory and Continued Access Cohorts patients previously enrolled in the IDE study will be evaluated annually through five (5) year follow-up. In addition, all patients enrolled in the original study cohorts as well as the continued access patients will be sent a letter questionnaire annually at the 6-10 year postoperative time point to assess the patient's general well-being and if the study components are still in place
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
(Patient must meet all of the following characteristics to be enrolled in the study):
- Males and females, 21 to 80 years of age, inclusive;
- Primary diagnosis of non-inflammatory arthritis (osteoarthritis) or inflammatory arthritis (rheumatoid arthritis), or patients requiring a revision as specified previously;
- The patient or his/her legal guardian is willing to consent to participate in the study by signing and dating the approved consent form;
- The patient will be available for follow-up through at least two years postoperative;
- The patient has met an acceptable preoperative medical clearance and is free or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk (FDA requirement);
- The patient has a total Harris Hip Score of less than or equal to 60 (FDA requirement);
- The patient meets none of the exclusion criteria.
Exclusion Criteria:
(Patient with any of the following characteristics must be excluded from the study):
- Patients known to have insufficient quantity or quality of bone support resulting from Conditions such as cancer, femoral osteotomy, Girdlestone resection, significant osteoporosis or metabolic disorders of calcified tissues. Patients with physical conditions tending to place extreme loads on implants such as morbid obesity (> 100 pounds over desirable body weight), Charcot joints, muscle deficiencies, or multiple joint disabilities;
- Patients with active localized or systemic infection;
- Patients who have not reached full skeletal maturity;
- Patient psychological or neurological conditions which tend to preempt the patient's ability or willingness to restrict activities or follow medical advice, especially during the postoperative period, e.g.: drug or alcohol abuse, serious mental illness or retardation, or general neurological conditions;
- The patient is participating in any other pharmaceutical, biologic or medical device clinical investigation;
- Immunosuppressive disorders - immunosuppressive disorders are chronic conditions characterized by markedly inhibited ability to respond to antigenic stimuli. Examples of such conditions include patients who are on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses), patients receiving therapy to prevent homograft rejection, patients who have acquired immunodeficiency syndrome (AIDS), or auto-immune diseases (except rheumatoid arthritis).
- Pregnancy.
- Patients with known sensitivity to materials in the device.
Contacts and Locations| United States, Georgia | |
| Medical College of Georgia, Department of Orthopaedics | |
| Augusta, Georgia, United States, 30912 | |
| United States, Michigan | |
| Family Orthopaedics | |
| Flint, Michigan, United States, 48507 | |
| United States, New York | |
| Hospital of Joint Disease, Orthopaedic Institute | |
| New York, New York, United States, 10003 | |
| United States, Pennsylvania | |
| Presbyterian Medical Center, Department of Orthopaedic Surgery | |
| Philadelphia, Pennsylvania, United States, 19104-2699 | |
| United States, Tennessee | |
| The Memphis Orthopaedic Group, PC | |
| Memphis, Tennessee, United States, 38104 | |
| United States, Texas | |
| University of Texas Medical Branch, Dept of Orthopaedics and Rehab | |
| Galveston, Texas, United States, 77555 | |
| United States, Vermont | |
| University of Vermont College of Medicine | |
| Burlington, Vermont, United States, 05405 | |
| Principal Investigator: | Scott Corpe, M.D. | Medical College of Georgia, Dept of Orthopaedic |
| Principal Investigator: | Joseph Zuckerman, M.D. | Hospital of Joint Disease, Orthopaedic Institute |
| Principal Investigator: | Jonathan P Garino, M.D. | Presbyterian Medical Center, Dept of Orthopaedic |
| Principal Investigator: | Michael J Grecula, M.D. | University of Texas Medical Branch, Dept of Orthopaedic |
| Principal Investigator: | James Howe, M.D. | University of Vermont |
| Principal Investigator: | Michael Lynch, M.D. | The Memphis Orthopaedic Group, PC |
| Principal Investigator: | Norman E Walter, M.D. | Family Orthopaedics |
More Information
No publications provided
| Responsible Party: | Smith & Nephew, Inc. |
| ClinicalTrials.gov Identifier: | NCT00663351 History of Changes |
| Other Study ID Numbers: | PMA 030022 |
| Study First Received: | February 28, 2008 |
| Last Updated: | December 18, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Smith & Nephew, Inc.:
|
Arthritis Osteoarthritis Traumatic Arthritis Degenerative Joint Disease Avascular Necrosis |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013